Malignant mesothelioma (MM) is an aggressive malignancy, highly resistant to current medical and surgical therapies, whose tumor cells characteristically show a high level of aneuploidy and genomic instability. We tested our hypothesis that targeting chromosomal instability in MM would improve response to therapy. Thr/Tyr kinase (TTK)/monopolar spindle 1 kinase (Mps-1) is a kinase of the spindle assembly checkpoint that controls cell division and cell fate. CFI-402257 is a novel, selective inhibitor of Mps-1 with antineoplastic activity. We found that CFI-402257 suppresses MM growth. We found that Mps-1 is overexpressed in MM and that its expression correlates with poor patients' outcome. In vitro, CFI-402257-mediated inhibition of Mps-1 resulted in abrogation of the mitotic checkpoint, premature progression through mitosis, marked aneuploidy and mitotic catastrophe. In vivo, CFI-402257 reduced MM growth in an orthotopic, syngeneic model, when used as a single agent, and more so when used in combination with cisplatin+pemetrexed, the current standard of care. Our preclinical findings indicate that CFI-402257 is a promising novel therapeutic agent to improve the efficacy of the current chemotherapeutic regimens for MM patients.
INTRODUCTION
Malignant mesothelioma (MM) is an aggressive cancer originating from the linings of the pleural, peritoneal and pericardial cavities. Epidemiologically, MM is associated to exposure to carcinogenic mineral fibers, such as asbestos. MM causes about 40 000 deaths per year worldwide and is characterized by a median survival of about 1 year. [1] [2] [3] [4] The standard first-line therapy for MM is the combination of a platinum derivative (for example, cisplatin) and an antimetabolite drug (for example, pemetrexed). 1, 5 However, chemotherapy only marginally impacts patients' survival because of MM intrinsic chemoresistance and polyclonal origin, which is related to the carcinogenic field effect of asbestos. 6, 7 Therefore, there is an urgent need to identify novel, more effective therapies.
Unlike lung cancer and other adult malignancies caused by exposure to carcinogens, MM has a very low average number of mutations, range 2-52, similar to pediatric malignancies. 8 Moreover, the few recurrently mutated driver genes in MM are tumorsuppressor genes, BAP1, NF2, CDKN2A, SETD2 and PBRM1, whereas activating mutations of oncogenes are rare. [8] [9] [10] [11] [12] [13] Instead, larger chromosomal aberrations and copy number variations, [14] [15] [16] [17] as well as non-contiguous minute deletions, 18 are commonly found in MM. These findings suggest that chromothripsis and widespread chromosomal instability are much more relevant in MM pathogenesis than nucleotide level activating mutations. These findings perfectly fit within a model of MM pathogenesis, caused by the concurrent activities of asbestos-induced DNA damage, 19 and inflammation, [20] [21] [22] acting in concert with genetic susceptibility and instability, 20, 23, 24 and possibly other cofactors. 25, 26 Very recently, the mechanisms of gene-environment interaction that lead to MM have been elucidated. 27, 28 We speculated that MM would develop adaptive mechanisms to tolerate genomic instability and aneuploidy, as seen in some other cancer types, 29, 30 and that these mechanisms could be exploited therapeutically. The spindle assembly checkpoint (SAC) is the main mechanism that maintains chromosomal stability through the cell division. [31] [32] [33] Thr/Tyr kinase (TTK), also known as monopolar spindle 1 (Mps-1) is a dual specificity, serine-threonine kinase and a critical SAC component. Mps-1 promotes the formation of the mitotic checkpoint complex, 31, 34 regulates proper alignment of chromosomes, 35 cytokinesis, 36 chromosome duplication 37 and the DNA damage response. 38 Mps-1 is overexpressed in several cancer types, as high levels of Mps-1 facilitate the survival of tumor cells with aneuploidy. 39, 40 In contrast, reduction of Mps-1 levels triggers SAC loss and elicits massive missegregation of chromosomes, which leads to cell death. [41] [42] [43] [44] Recently, Mps-1 emerged as a potential therapeutic target in cancer, especially in combination with chemotherapy. 43, 45, 46 RESULTS AND DISCUSSION We used a publicly available TCGA database 47 to analyze survival data of 56 MM patients for the correlation between Mps-1 mRNA expression levels and the time of death from initial MM diagnosis. Mps-1 mRNA levels significantly correlated with a shorter patients' survival (r = − 0.41; 95% CI − 0.61 to − 0.17; P o0.01) (Figure 1a) . We dichotomized cases in Mps-1 high and Mps-1 low , based on whether mRNA levels were above or below the median value, and analyzed survival comparing Kaplan-Meir curves with log-rank test. Mps-1 high MM cases had significantly shorter survival compared with Mps-1 low MM cases (median survival 254 days vs 699 days; hazard ratio 0.42; 95% CI 0.24-0.75; P o 0.001) (Figure 1b) . Analysis of the TCGA data set, also uncovered that Mps-1 mRNA expression was significantly higher in nonepithelioid (non-E) histologic subtypes (biphasic, sarcomatoid and diffuse MM-as per TCGA classification), as compared with the epithelioid subtype (Supplementary Information 1) . Conversely, no correlation between Mps-1 mRNA expression and different tumor stages was found (Supplementary Information  1) . Overall, because non-E MMs are more aggressive and have a worse prognosis, 48 the higher Mps-1 expression in the non-E could, at least in part, explain the association between high Mps-1 expression and poor survival. Using the TCGA mesothelioma data set, a comparison of mRNA and copy number variation indicated that overexpression of Mps-1 mRNA (that is, highest quartile), was significantly more common in MMs harboring CDKN2A homozygous or heterozygous deletions (log odds ratio = 2.33, Po 0.001), whereas no statistical association was found between Mps-1 mRNA overexpression and deletions in the other commonly altered MM tumor-suppressor genes, BAP1 and NF2. Next, we compared Mps-1 mRNA and protein levels from a panel of MM lines and from human mesothelial primary cell cultures (HM) that we routinely establish from pleural fluids of patients with nonmalignant conditions. 49 Mps-1 expression was consistently and significantly higher among all MM cell lines, compared with HM tissue cultures (1.03 ± 0.25 vs 0.13 ± 0.06, P = 0.043) (Figure 1c ).
In line with the mRNA data, protein levels of Mps-1 were higher in MM cell lines (Figure 1d ). Together, these data supported the hypothesis that Mps-1 may be critical for the development of MM and that it could represent a useful novel therapeutic target.
The initial effect of SAC abrogation, through inactivation of Mps-1, is manifested by an accelerated entry into a mitotic process, which can be assessed by measuring the phosphorylation of histone H3 on Ser10 and Ser28 residues (phospho-H3). 50 This process eventually results in exaggerated aneuploidy, mitotic catastrophe and cell death. 43 We, therefore, evaluated the effects of Mps-1 inhibition in MM cells using CFI-402257, a recently discovered, specific and potent small molecule inhibitor of Mps-1.
46,51
Western blot analyses showed reduced levels of phospho-H3 in CFI-402257-treated compared with dimethyl sulfoxide (DMSO)-treated MM cell lines, after release from nocodazole-induced G2/M arrest ( Figure 2a ). The result was confirmed in a microscopy timecourse analysis ( Figure 2b ). These findings are consistent with reduced SAC function and accelerated progression through the cell cycle. Next, we studied the impact of Mps-1 inhibition with CFI-402257 on the first and the second round of division of MM cells. Treatment with CFI-402257 was associated with increased frequency of errors, such as misaligned and lagging chromosomes, observed in meta-and anaphase, inter-nuclear bridging in telophase or unequal chromosome separation, and consequent unequal division, multilobulation and formation of micronucleus (Table 1 , Supplementary Information 2). In addition, CFI-402257-induced perturbations in cell cycle, led to an increase in the proportion of aneuploid cells, manifested as a widening of the peaks in cytofluorometric analysis of DNA content (Figure 2c ). No significant polyploidy was observed with concentration as high as 3 μM, which agrees with previous reports 46 and confirms the selectivity of the compound (Supplementary Information 3) . The massive aneuploidy observed, should not be tolerated. Accordingly, CFI-402257-treated MM cells ultimately underwent cell death with features characteristic of mitotic catastrophe, 52 as shown by cytoplasmic translocation of the cytochrome c (Figure 2d upper panel) and cleavage of caspase-3 and poly (ADP-ribose) polymerase (Figure 2d lower panel) . Together our results showed that CFI-402257 leads MM cells to exit mitosis with mis-segregated chromosomes, resulting in exaggerated aneuploidy and consequent cell death.
Our observations were paralleled by the specific effect of CFI-402257 on MM cells viability, with EC50 values ranging between 20 and 40 nM (Figure 3a) , whereas three normal primary HM cultures (from different donors) were largely unaffected at these same concentrations (Figure 3b) . Moreover, treatment with CFI-402257 showed a tendency to decrease the number of MM colonies in a soft agar assay (Supplementary Information 4) , which closely mimics tridimensional tumor growth, and CFI-402257 significantly reduced colony size (Mill: 67.8% (10 nM) and 46% (100 nM), P o 0.0001; Phi: 57.4% (10 nM), P = 0.0016 and 36.4% (100 nM), P o0.0001; Figure 3c ).
Cisplatin+pemetrexed (Cis/Pem) is the current first-line standard of care for MM, and it is associated with a modest average extended survival of about 11 weeks. 5 We hypothesized that Mps-1 inhibition could synergize with cisplatin-induced cell death. We found that CFI-402257 and cisplatin have a synergistic effectcombined effect of the coefficient of drug interaction (CDI) value below 1, in vitro, in both Hmeso, a relatively cisplatin-sensitive MM line, and Mill, a relatively cisplatin-resistant line (CDI = 0.652 for Hmeso; CDI = 0.86 for Mill; Figure 3d) .
We tested the efficacy of CFI-402257 in an orthotopic, syngeneic model of MM, using the well-characterized AB12 murine MM cell To assess cytochrome c (Cyt c) release (top panel) after 72 h of treatment, fractionation was performed by incubation of harvested cells in lysis buffer (20 mM HEPES-KOH pH 7.5, 10 mM KCl, 1.5 mM MgCl2, 1 mM bisodium ethylenediaminetetraacetic acid (EDTA), 1 mM EGTA, sucrose) and aspiration through a 22-gauge needle followed by centrifugation at 1000 g for 5 min at 4°C to separate nuclei. The supernatant was centrifuged at 10 000 g for 20 min in 4°C to separate mitochondria. The cytoplasmic fraction was immunoblotted and Cyt c (#556432, BD, San Jose, CA, USA) was detected. After 5 days of treatment, total lysates of Ren, Mill, Phi and Hmeso were collected and immunoblotted. Caspase-3 and poly(ADP-ribose) polymerase (PARP; #9662 and #9542, Cell Signaling) were detected (bottom panel), α-tubulin and GAPDH served as a loading control. All the data are representative of two independent experiments. For space constraints, 'Hme' stands for 'Hmeso' MM cell line. DMSO, dimethyl sulfoxide.
line. 53 Similar to human MM cells, AB12 in vitro growth was inhibited by CFI-402257 at nanomolar concentrations (Supplementary Information 5a). Mice were injected intraperitoneally with AB12 cells carrying luciferase gene. Six days later, following the establishment of the tumors, as detected by in vivo imaging system, mice were randomized to receive (1) vehicle (PEG), (2) CFI-402257 alone (7 mg/kg), (3) Cis/Pem, for 2 weeks followed by CFI-402257 till study end-point or (4) Cis/Pem, discontinued after 2 weeks, as a control (Figure 4a) . The Cis/ Pem-CFI-402257 combination regimen adopted in our in vivo study, was chosen to mimic the approach of approval process for the use of new drugs in clinic. Treatments were well tolerated, as we did not observe overt toxicity or any weight loss upon CFI-402257 treatment as single agent. Less than 10% of body mass loss was observed in the Cis/Pem-CFI-402257 regimen group (Supplementary Information 5b) .
To compare tumor growth rates among the four treatment groups, we ran mixed (repeated observations over time) polynomial regression analyses, which accounted for nonlinear growth. The outcome was tumor radiance and the predictors were To determine the effects of drug combinations CDI was calculated 58 as follows: CDI = AB/(A × B), where AB is the ratio of the measured effect of combination to control group; A or B is the ratio of the single agent to control group. Thus, CDI o1, = 1 or 41 indicates that the drugs are synergistic, additive or antagonistic, respectively. CDI o0.7 indicates that the drug is significantly synergistic. ** Po 0.005; **** Po 0.0001. groups, days of growth and the square of days. To assess group differences in growth rate, the interaction term between group and days was included, providing a slope comparison test. Tumor size was assumed to be zero at zero days. The mixed procedure in the SAS 9.4 software (SAS Institute Inc., Cary, NC, USA) performed the analyses. Kaplan-Meier survival curves were compared using the log-rank (Mantel-Cox) test using GraphPad Prism 7.0 (GraphPad Software).
We found that CFI-402257 had moderate antitumor effect, as a single agent, and significant effect when added to the standard chemotherapy regimen. Specifically, we found that CFI-402257 treatment alone significantly reduced tumor growth compared with vehicle treatment (t(51) = − 3.6, P = 0.0008), although to a lesser extent compared with standard chemotherapy. More importantly, CFI-402257 synergized with chemotherapy to significantly delay tumor growth, after cessation of standard chemotherapy (t(71) = 4.9, P o 0.0001) (Figures 4a and b) . Reduction in tumor growth resulted in significantly prolonged overall survival in treated mice in both CFI-402257 treatment alone Information 5c and d) . Short-term in vivo experiment to study the mechanism of CFI-402257 in vivo revealed evidence of mitotic errors in the tumor tissue harvested from CFI-402257-treated animals (Figure 4c ). Quantification of phospho-H3 (S10)-positive nuclei, revealed a reduction of the mitotic index in CFI-402257-treated tumors (0.68 for vehicle vs 0.46% for 7 mg/kg dose, P = 0.0001 and 0.1% for 35 mg/kg dose, P o 0.0001) (Figure 4c) .
The low mutational load in MM 8 and its frequent polyclonal origin, 7 provide a rationale for the observation that targeted therapies for MM have been ineffective. Accordingly, the prognosis and the median survival of MM have depressingly remained almost unchanged over the past several decades. We reasoned that new therapeutic strategies should aim at targeting common mechanisms required for survival of all tumor cells, rather than uncommon activating mutations of oncogenes in MM, which are present only in some but not all tumor cells. Genome instability in the context of cancer cells is considered an 5 AB12-luc cells. Tumors were allowed to develop for 15 days then mice were randomized into vehicle (PEG), CFI-402257 (7 mg/kg) and CFI-402257 (35 mg/kg). CFI-402257 was administered through oral gavage twice a day, for 5 days. On day 6, mice were killed and tumors were collected. Graph shows the mean ± s.e. m. of the percentage of phospho-H3 (S10)-positive nuclei counted from 20 images taken from each tumor tissue. ***P o0.01, ****P o0.0001. P-values were calculated using Student's t-test. Picture shows staining with phospho-H3 (S10) antibody depicting (yellow arrow) chromosome loss during the cell division in CFI-402257-treated tumor tissue. Bar; 10 μm.
example of hormesis, a process that exhibits a biphasic response, with beneficial effects at low levels, but lethal at higher levels. 45, 54 Hence, exacerbation of aneuploidy targeting SAC components eventually cannot be tolerated. For this reason, mitotic kinases are now considered effective 'druggable' targets in cancer therapy. The chemistry and pharmacology of kinase inhibitors have developed over the last two decades to enable oral administration. 55 CFI-402257 or N-cyclopropyl-4-(7- ((((1 s,3 s)-3-hydroxy-3-methylcyclobutyl) CFI-402257 has recently entered a phase 1 clinical trial that is aimed to study safety, tolerability and pharmacokinetics of the compound in patients with advanced solid cancers (ClinicalTrails. gov Identifier: NCT02792465).
Here, for the first time we targeted chromosomal instability in MM. We found that inhibition of Mps-1 selectively suppressed viability of MM enabling cells to bypass the SAC and causing perturbations of the mitotic process, ultimately leading to cell death. Importantly, CFI-402257 was effective in an orthotopic, syngeneic MM model. We demonstrated that the mitotic kinase Mps-1, so far unrecognized as a contributing factor in the pathology of MM, constitutes a promising therapeutic target. We propose that CFI-402257 fits the criteria for further clinical investigation and could offer a novel therapeutic approach to patients with MM. Based on our in vivo data, the potential clinical application of CFI-402257 would be beneficial in combination with established chemotherapeutic regimens. Adding CFI-402257 to the first-line treatment should benefit those patients who fail to respond to conventional chemotherapy. It is hoped that future biomarker studies may help identify those patients that are more likely to benefit from this therapy. 11, 56, 57 ABBREVIATIONS Cis/Pem, cisplatin/pemetrexed; MM, malignant mesothelioma; Mps-1, monopolar spindle 1; TTK, dual specificity Thr/Tyr kinase.
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